key: cord-0952921-1bc0qq7w
authors: La Milia, Vincenzo; Bacchini, Giuseppe; Bigi, Maria Carla; Casartelli, Donatella; Cavalli, Andrea; Corti, Mauro; Crepaldi, Monica; Limardo, Monica; Longhi, Selena; Manzoni, Celestina; Ravasi, Chiara; Stucchi, Valentina; Viganò, Sara
title: COVID-19 outbreak in a large hemodialysis centre in Lombardy, Italy
date: 2020-05-24
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2020.05.019
sha: b5976a3d14a9a92d240c0e69c5a51cb1a5501957
doc_id: 952921
cord_uid: 1bc0qq7w

nan

On December 31, 2019, China reported the first cases of pneumonia of unknown cause that would later be identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1-3). SARS-CoV2 rapidly spread, resulting in a pandemic, and as of April 10, 2020 there were almost 1. Patients undergoing hemodialysis (HD) treatment and health care staff may be at high risk of Covid-19 due both to the difficulty in applying isolation and social distancing, and the immunosuppressed state and frailty of patients (5) .

There are little data available from China (5-6) on the prevalence of SARS-CoV-2 infection in HD patients and no data on HD patients from other countries.

We report the experience of a large HD centre in Lombardy, Italy, during the SARS-CoV-2 epidemic in March 2020.

During the first 2 weeks of March, 7 HD patients (5 from the HD hospital and 2 from the HD satellite centres) died from causes unrelated to SARS-CoV-2 infection (2 from cachexia, 2 from Staphylococcus Aureus sepsis, 1 from sudden death and 2 from voluntary interruption of hemodialysis treatment). On March 9 the first HD patient, was admitted to hospital for interstitial pneumonia with positive nasopharyngeal swab for SRAS-CoV-2. From March 9 to March 26, a total of 26 HD patients were admitted for fever. Of these, 21 (81%) patients (7 from the satellite centers) tested positive for SARS-CoV-2 and they all had interstitial pneumonia. Thereafter, the incidence of new cases of HD COVID-19 patients was almost linear from March 9 to 26 (Figure 1a ). In the same month, no patient on peritoneal dialysis was admitted for COVID-19 and none of these patients developed symptoms due to SARS-CoV-2 infection at home.

Among the 25 COVID-19 patients hospitalized, 13 (52%) died, 7 (28%) improved and discharged and 5 (20%) are still hospitalized. The cause of death was acute respiratory failure in 8 patients and worsening neurological conditions in 5 patients. There were no statistically significant differences in age (73±8 years vs 72±15 years), dialysis vintage (55±15 months vs 39±9 months), major comorbidities (2±0 vs 1±0) and therapy (all patients were treated with anti-viral therapy, hydroxychloroquine, azithromycin and low molecular weight heparin) between the COVID-19 patients who died and the COVID-19 patients who were discharged or are still hospitalized.

All HD COVID-19 patients received respiratory support (oxygen therapy with nasal cannulae, masks or non-invasive positive pressure ventilation) but not mechanical ventilation. Patients died after a median of 8 days (IQR 5-11) from admission. Patients who recovered were discharged after a median of 15 days (IQR 13-16) from admission.

COVID-19 presents particular challenges for patients on dialysis, in particular for those undergoing treatment in HD centers. In-center HD significantly increases the risk of transmission of infection, including to medical staff, patients themselves and family members, due to the difficulty in apply epidemiological measures, such as isolation and social distancing. It is well known that asymptomatic SARS-CoV-2 carriers can transmit the infection (S1) and this is fact is important in transmission of the virus in areas such as waiting rooms, HD rooms and the shared transportation to and from the HD centres. In HD rooms, it is not always possible to maintain the recommended safety distance of about 2 meters (S2), and patients cannot always tolerate the surgical mask for long periods of time. Due to the high incidence of patients and healthcare professionals with COVID-19 symptoms, we decided to perform a nasopharyngeal swab for SARS-CoV-2 in all asymptomatic patients of the 4 outpatient HD centers: of these, 18% (33/188) were found positive. Before performing nasopharyngeal swab SARS-CoV-2, patients underwent dialysis sessions in the same rooms and although healthcare professionals wore the appropriate PPE, but not the PPE reserved for patients known to be SARS-CoV-2 positive. Upon receiving swab results, we embarked on a different strategy. We transferred all patients who tested positive from the satellite centres to the hospital centre and created three distinct areas for patients on HD treatment: one for positive asymptomatic, one for positive symptomatic and one for negative ( Figure 5 ). After having deployed these preventive measures, we had no more cases of COVID-19 among the previously negative patients and among the healthcare staff. Four patients with positive swab subsequently developed symptoms for With these measures, probably, it was possible to reduce the incidence of COVID-19 transmission among HD patients in our dialysis centres obtaining the flattening and then the inversion of the incidence curve (Figure 1b) . The mortality of COVID-19 in general popolation has been observed to be around the 2.3%, with age and comorbidities such as cardiovascular diseases, diabetes, chronic respiratory diseases, hypertension and cancer being associated with worse prognoses (S3).

There are no data on COVID-19 mortality in HD patients. Unlike other limited experiences (6), (52%) mortality in our HD patients was very high: 13 of 25 patients with COVID-19 died.

All HD patients with COVID-19 were treated with anti-viral therapy, hydroxychloroquine, antibiotics (azithromycin) and low molecular weight heparin and there were no statistically significant differences in age, dialysis vintage, major comorbidities between the COVID-19 patients who died and the COVID-19 patients who were discharged or still hospitalized. A factor explaining such high mortality may be the mean age of the HD patients in our HD centres, however the high mortality among HD patients indicates a vulnerability towards a severe viral infection.

It is possible that the attenuation of the incidence of HD patients with COVID-19 is also due to the and not to the measures that we have put course of the epidemic in the territory of our province in place as well as it is possible that we have not identified all patients positive to SARS-CoV-2 for the non-absolute sensitivity of the nose-pharyngeal swab (S4). However, ours is the first report of attempted containment in HD centres, in addition to general measures, of the SARS-CoV-2 epidemic in areas where there has been a very high spread of the virus such as in our territory.

In the absence of other measures to detect asymptomatic carriers of SARS-CoV-2, performing a naso-pharyngeal swabs on all HD patients, separating positive and negative patients during HD transport and treatment and upgrading the PPE for staff may represent a useful attempt to counter the spread of COVID-19. Furthermore, the absence of COVID-19 infections among our PD patients, compared to the very high incidence among our HD patients, suggests that self-quarantine and social distancing are the most effective measures for the containment of the spread of the SARS-CoV-2 epidemic in patients on dialysis treatment.

The authors declare no conflict of interest. Even-day HD shifts (Tuesday-Thursday-Saturday) Figure 5 

World Health Organization. Pneumonia of unknown cause -China

World Health Organization. Novel Coronavirus -China

A novel coronavirus from patients with pneumonia in China

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Last Updated

Lessons from the Experience in Wuhan to Reduce Risk of COVID-19

Infection in Patients Undergoing Long-Term Hemodialysis. CJASN 15: ccc-ccc

On the Frontline of the COVID-19 Outbreak Keeping Patients on Long-Term Dialysis Safe. CJASN 15: ccc-ccc

COVID-19 infection in kidney transplant recipients